Literature DB >> 1295477

Tissue-specific induction of metallothionein by bismuth as a promising protocol for chemotherapy with repeated administration of cis-diamminedichloroplatinum (II) against bladder tumor.

Y Kondo1, M Satoh, N Imura, M Akimoto.   

Abstract

The effects of bismuth nitrate pretreatment on the toxicity and antitumor activity of repeatedly administered cis-diamminedichloroplatinum (Cisplatin; CDDP) were examined using nude mice inoculated with human bladder tumor tissues. Lethal and renal toxicities exerted by the repeated administration of CDDP were effectively prevented by pretreatment with bismuth (Bi) without affecting its antitumor activity against transplanted human bladder tumor as in the case of single dose of the drug reported previously. The renal Bi level was gradually increased with the frequency of Bi administration, and metallothionein (MT) induced by Bi in the kidneys maintained its substantially high level during the treatment. It was confirmed that MT was not induced in the tumors even by the 5 cycles of repeated Bi administration. This specific protection shown by the Bi preadministration against the toxicity of repeatedly injected CDDP can be explained by the fact that Bi markedly induces MT in the kidney, a major target organ of CDDP toxicity, but not in the tumor tissues inoculated in the nude mice, probably because Bi is efficiently taken up by the kidney but hardly incorporated into the tumor tissues as reported previously. These data obtained by repeated doses of CDDP as described above strongly suggest a promising protocol for chemotherapy using CDDP with Bi compounds, a tissue specific MT inducer, against advanced bladder tumor in human.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1295477

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  The cytotoxic interaction of inorganic trace elements with EDTA and cisplatin in sensitive and resistant human ovarian cancer cells.

Authors:  R H Maier; S M Purser; D L Nicholson; W J Pories
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-03       Impact factor: 2.416

2.  Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot study.

Authors:  Per Boye Hansen; Milena Penkowa
Journal:  Support Care Cancer       Date:  2016-12-13       Impact factor: 3.603

3.  Effect of pharmacologic doses of zinc on the therapeutic index of brain tumor chemotherapy with carmustine.

Authors:  N Roosen; F Doz; K L Yeomans; D V Dougherty; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  A bismuth diethyldithiocarbamate compound induced apoptosis via mitochondria-dependent pathway and suppressed invasion in MCF-7 breast cancer cells.

Authors:  Pit Foong Chan; Kok Pian Ang; Roslida Abd Hamid
Journal:  Biometals       Date:  2021-02-08       Impact factor: 2.949

Review 5.  Current and potential applications of bismuth-based drugs.

Authors:  Donal M Keogan; Darren M Griffith
Journal:  Molecules       Date:  2014-09-23       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.